Innovations in classical hormonal targets for endometriosis

Nicola Pluchino, Letizia Freschi, Jean-Marie Wenger, Jean‐Marie Wenger, Isabelle Streuli
Expert review of clinical pharmacology · 2015 · vol. 9(2) , pp. 317–327 · doi:10.1586/17512433.2016.1129895 · PMID:26645363 · W2195339775
review OA: green CC0 ⤵ 13 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This paper reviews therapeutic strategies and new molecule development targeting classical hormonal mechanisms, like estrogen and progesterone pathways, to treat endometriosis while considering wider biological impacts.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This review paper discusses endometriosis and the “classical” hormonal targets used or proposed for endometriosis pharmacotherapy, focusing on how estrogens and progesterone pathways contribute to endometrial-like abnormal tissue biology, including effects on inflammation, pain, and infertility. It summarizes advances in drug design approaches related to hormonal metabolism and signaling, framed in terms of endometrium abnormalities and downstream processes such as cell proliferation and movement. A key limitation is that, as a review, it synthesizes prior work rather than presenting new experimental data or a single study population. This paper is centrally about endometriosis — it specifically reviews innovations in classical hormonal targets (estrogen and progesterone-related mechanisms) for endometriosis drug therapy.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is a chronic disease of unknown etiology that affects approximately 10% of women in reproductive age. Several evidences show that endometriosis lesions are associated to hormonal imbalance, including estrogen synthesis, metabolism and responsiveness and progesterone resistance. These hormonal alterations influence the ability of endometrial cells to proliferate, migrate and to infiltrate the mesothelium, causing inflammation, pain and infertility. Hormonal imbalance in endometriosis represents also a target for treatment. We provide an overview on therapeutic strategies based on innovations of classical hormonal mechanisms involved in the development of endometriosis lesions. The development phase of new molecules targeting these pathways is also discussed. Endometriosis is a chronic disease involving young women and additional biological targets of estrogen and progesterone pharmacological manipulation (brain, bone and cardiovascular tissue) need to be carefully considered in order to improve and overcome current limits of long-term medical management of endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosisinfertility

MeSH descriptors

Endometriosis Estrogens Progesterone Animals Cell Movement Cell Proliferation Drug Design Endometriosis Endometriosis Endometrium Endometrium Estrogens Female Humans Infertility, Female Infertility, Female Inflammation Inflammation Inflammation Pain

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (56)

Cited by (13)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:17:33.600579+00:00
License: CC0 · commercial use OK